Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis

Metry, Andrew; Pandor, Abdullah; Ren, Shijie; Shippam, Andrea; Clowes, Mark; Dark, Paul; McMullan, Ronan; Stevenson, Matt

doi:10.3310/NAFW3527

An error occurred retrieving publication content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Extended Research Article

Toolkit

View Award

Andrew Metry , Abdullah Pandor , Shijie Ren , Andrea Shippam , Mark Clowes , Paul Dark , Ronan McMullan & Matt Stevenson .

Detailed Author information
Detailed Author information

Andrew Metry ^1,^*, Abdullah Pandor ¹, Shijie Ren ¹, Andrea Shippam ¹, Mark Clowes ¹, Paul Dark ^2,³, Ronan McMullan ⁴, Matt Stevenson ¹

¹ School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK
² The University of Manchester, Manchester, UK
³ Northern Care Alliance NHS Foundation Trust (Salford Care Organisation), Salford, UK
⁴ School of Medicine, Dentistry and Biomedical Sciences, Wellcome Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast, UK
^* Corresponding author Email: a.metry@sheffield.ac.uk

Disclosure of interests of authors

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, or available in the tool kit on the NIHR journals Library report publication page at https://doi.org/10.3310/NAFW3527.

Primary conflicts of interest: Paul Dark is the National Deputy Medical Director of the National Institute for Health and Care Research Clinical Research Network. He is a Local Principal Investigator for both the RECOVERY and REMAP-CAP platform trials, NIHR Urgent Public Health (UPH) pandemic research Advisory Group Lead Link for REMAP-CAP and specialist member of NIHR UPH Advisory Group. His NHS host hospital Research and Innovation Department has been contracted and paid to provide advice on the use of tocilizumab for Roche and sotrovimab for GlaxoSmithKline both in COVID-19. He supported the activity as a named NHS expert employed by the Northern Care Alliance NHS Foundation Trust (Salford Care Organisation) but received no personal payments. Ronan McMullan received grants or had contracts with NIHR HTA programme, NIHR Efficacy and Mechanisms Evaluation Programme, Medical Research Council (MRC) and Invest Northern Ireland (with Randox Lab Ltd). He was also paid honorarium for giving a lecture from Gilead Sciences Ltd in the past 36 months. Matt Stevenson provided advice to AstraZeneca Rare Disease regarding an unrelated intervention in an unrelated disease area. There are no other conflicts of interest within this project team.

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Report Content

Full Report
Abstract
Plain English Summary
Plain Language Summary
Scientific Summary

The full text of this issue is available as a PDF document from the Toolkit section on this page.

Responses to this report

No responses have been published.

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors. Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

Enter response message*

Name (title, first name, last name)*

Occupation / Job title*

Affiliation / Employer*

Email*

Other authors
For example, if you are responding as a team or group. Please ensure you include full names and separate these using commas

Statement of competing interests
We believe that readers should be aware of any competing interests (conflicts of interest).
The International Committee of Medical Journal Editors (ICMJE) define competing interests as including: financial relationships with industry (for example through employment, consultancies, stock, ownership, honoraria, and expert testimony), either directly or through immediate family; personal relationships; academic competition; and intellectual passion.

If yes, please provide details below

Enter response title*

Enter CAPTCHA What is three plus zero?*

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document